Repligen (NASDAQ:RGEN) Corporation (NASDAQ: RGEN) has reported a mixed second quarter, with a decline in Chinese demand impacting overall performance, despite positivQe growth in other areas. The company narrowed its revenue guidance for 2024 to $620 million to $635 million, reflecting these challenges as well as increased foreign exchange headwinds. However, Repligen remains optimistic about future growth prospects, driven by new modality adoption and a strong funnel of opportunities, including the pending acquisition of Tantti Lab.
Key Takeaways
- Repligen's Q2 performance showed growth in orders and revenues, with orders 2% above revenues.
- Sales in pharma and CDMOs were positive, with growth in consumables and equipment orders.
- The company experienced a drop in demand in China and headwinds in proteins and COVID.
- Revenue guidance for 2024 was narrowed to $620 million to $635 million.
- Non-COVID growth is projected at 11%, with a strong second half expected.
- Repligen reported $154 million in revenue for Q2, a 3% year-over-year decline.
- Adjusted operating margin is expected to reach 12-13% in the second half, with EBITDA margins at 17-18%.
- The company's key account strategy covers 20 top accounts and has been successful.
Company Outlook
- Repligen anticipates stronger revenue growth in the second half of 2024.
- The company expects to rebound in proteins in 2025 and sees long-term growth above the market rate.
- A 7% increase in margins is projected for the second half of 2024.
- Repligen plans to discuss 2025 plans at the end of the year, aiming to grow above market rates.
Bearish Highlights
- The company revised its 2024 revenue guidance downward due to decreased demand in China and foreign exchange headwinds.
- There was a 3% year-over-year decline in Q2 revenue.
Bullish Highlights
- Tangenx product demand accelerated, up 30% year-over-year.
- Chromatography demand increased by over 50% in the quarter.
- The ARTeSYN product line and OPUS portfolio showed positive growth.
Misses
- Repligen's revenue for the second quarter fell short of the previous year's by 3%.
Q&A Highlights
- Executives discussed the order book, seasonality, and forecast accuracy.
- They addressed the challenges in the Chinese market and the company's strategy to improve margins.
- The growth of CDMOs was attributed to the end of destocking and increased project activity.
Repligen Corporation remains confident in its market position and capacity to support demand. The company's innovative product portfolio and key account program are expected to contribute to future growth. Despite the setbacks in the Chinese market, Repligen's diversified offerings and strategic acquisitions position it well for a rebound in the coming years. The next earnings call is scheduled for November, where further updates on the company's performance and outlook will be provided.
InvestingPro Insights
Repligen Corporation's recent performance and future outlook present a mixed picture, with some key metrics and analyst insights that investors should consider. According to InvestingPro data, Repligen has a market capitalization of $9.45 billion, reflecting its significant presence in the bioprocessing industry. Despite the challenges in the Chinese market, Repligen has seen a strong return over the last week, with a price total return of 22.22%. This short-term spike may interest traders, but long-term investors might be more concerned with the company's profitability and valuation multiples.
InvestingPro Tips suggest caution; with five analysts revising their earnings downwards for the upcoming period, it indicates potential headwinds that could affect future profitability. Additionally, the Relative Strength Index (RSI) suggests that the stock is currently in overbought territory, which could imply a pullback in the near term.
From a valuation standpoint, Repligen is trading at a high EBITDA valuation multiple, with a P/E ratio (adjusted) for the last twelve months as of Q2 2024 at 1354.99, significantly above industry averages. This high valuation could be a concern for value-oriented investors, particularly given the company's revenue decline of 17.41% over the same period.
Investors looking for more in-depth analysis and additional InvestingPro Tips can find them on the InvestingPro platform, where 9 more tips related to Repligen are available, offering a comprehensive view of the company's financial health and market position.
Overall, while Repligen's strategic initiatives and product demand growth are bullish indicators, the InvestingPro Insights suggest that investors should weigh these against the backdrop of revised earnings, valuation concerns, and recent stock performance to make informed decisions.
Full transcript - Repligen Corp (RGEN) Q2 2024:
Operator: Good day, ladies and gentlemen, and welcome to Repligen Corporation's Second Quarter of 2024 Earnings Conference Call. [Operator Instructions]. I would now like to turn the call over to your host, Sondra Newman, Head of Investor Relations for Repligen. Please go ahead.
Sondra Newman: Thank you, and welcome to our second quarter of 2024 report. On this call, we will cover business highlights and financial performance for the three- and six-month period ending June 30, 2024, and we will provide financial guidance for the year 2024. Joining us on the call today are Repligen's current Chief Executive Officer, Tony Hunt; our Chief Commercial Officer, Olivier Loeillot, and our Chief Financial Officer, Jason Garland. As a reminder, the forward-looking statements that we make during this call, including those regarding our business goals and expectations for the financial performance of the company, are subject to risks and uncertainties that may cause actual events or results to differ. Additional information concerning risks related to our business is included in our quarterly reports on Form 10-Q, our annual report on Form 10-K, and other current reports on 8-K, including the report that we're filing today and other filings that we make with the Securities and Exchange Commission. Today's comments reflect management's current views, which could change as a result of new information, future events or otherwise. The company does not obligate or commit itself to update forward-looking statements, except as required by law. During this call, we are providing non-GAAP financial results and guidance, unless otherwise noted. Reconciliations of GAAP to non-GAAP financial measures are included in the press release that we issued this morning, which is posted to Repligen's website and on sec.gov. Adjusted non-GAAP figures in today's report, include the following, base revenue and organic revenue, non-COVID and non-protein revenue, cost of sales, gross profit and gross margin, operating expenses, including R&D and SG&A, income from operations and operating margins, other income, pretax income, tax provision, effective tax rate, net income, diluted earnings per share, as well as EBITDA, adjusted EBITDA, and adjusted EBITDA margins. These adjusted financial measures should not be viewed as an alternative to GAAP measures, but are intended to best reflect the performance of our ongoing operations. Now, we’ll turn the call over to Tony Hunt.
Tony Hunt: Thank you, Sondra, and good morning, everyone, and welcome to our Q2 earnings call. As you saw in our press release this morning, we reported on an improving quarter for both revenues and orders, with orders pacing 2% above revenues for the second quarter and 1% or above revenues for the first half of the year. As outlined on our May earnings call, we were looking for continued momentum in Q2, and with the exception of seeing China demand decline further and the known headwinds in proteins and COVID, we had a really good quarter. We saw positive Q2 and year-to-date sales and order performance in pharma, and a healthy pickup in CDMO order activity. Sales and order momentum on consumables continued, and we saw it bounce back in equipment orders both sequentially and year-over-year. And finally, our momentum in the new modality space continued, with first half revenues and orders well above the same period in 2023. We are narrowing revenue guidance within our range, with the expectation that we will finish 2024 between $620 million to $635 million, which lowers our midpoint by 1%. This is directly related to the demand drop off in China where we saw a weak Q2, which is driving an additional $10 million decline versus our May call. We're also seeing increased headwinds coming from FX, but overall, we're really happy with the progress we're seeing, including the strategic direction being reinforced for proteins, with pending acquisition of Tantti Lab that we announced yesterday. So, moving now to the big picture on the quarter and the first half of 2024. Pharma revenues in Q2 were up about 15% sequentially and 20% year-on-year. Pharma orders were also strong, up 5% sequentially and 40% year-on-year. For CDMOs, while Q2 sales were down as anticipated, orders, as noted earlier, came in strong, up by 20% plus, both sequentially and year-over-year. Book-to-bill for CDMO was over 1.4 for the quarter and 1.1 for the first half of the year. This improvement was driven by an uptick in tier two CDMO activity, which we view as an important turn for emerging biotech and the overall biologics market. We look forward to seeing how this plays out later in the year and into 2025. Consumables maintained their momentum in Q2, with revenues up double-digit versus Q1. Orders in Q2 were up 30% versus prior year and in line with our Q1 orders. With consumable orders up 20% in the first of the year, we are confident that destocking is finally behind us. Moving to capital equipment, similar to CDMOs, equipment was light on revenue in the quarter. We did, however, see first half equipment sales up close to 10% versus the first half of 2023. More importantly, equipment orders showed a very nice rebound, up 20% versus last quarter and about 15% year-to-date on relatively easy comps. Supporting our order strength in H1 is the early success of our RS Systems product line where we have seen important wins at strategic accounts in Q2, including the first placements of our most recently launched RS 10 system. While the Q2 results are encouraging, there are still headwinds in this part of the market. However, we still expect capital equipment orders to pick up further in the second half, as we have a very strong opportunity funnel that we expect to convert to orders. The new modality customer base delivered mid-single digit revenue growth in Q2 versus the same quarter in 2023. New modality orders were up more than 40% year-over-year, delivering a Q2 book-to-bill of 1.1. First half of the year revenues were up greater than 10%, and more importantly, orders were up greater than 20% in the same period. This reflects the momentum we are seeing in this market and the strong portfolio fit for this customer base. Our regions continue to perform well, with the exception of China. China orders and sales were down again in Q2, and our expectation is that China revenues will now command around $25 million in 2024, or about $10 million lower than we were anticipating at the time of our Q1 call. Jason will cover more in his finance section on regional dynamics. So, in summary, total Q2 revenues decreased 3% year-over-year, but were up 4% if you exclude non-COVID and proteins headwinds. Sequentially, total Q2 revenues were up 2%. We continue to see some lumpiness on a franchise level from quarter to quarter, but sales through the first half of 2024 support our view that our franchises are recovering. Further validating this view is orders performance in the quarter and first half. Total orders in Q2 were up 20% year-over-year and up 30% if you exclude proteins. Sequentially, orders were up 5%. Moving to our updated revenue guidance for 2024. As noted earlier, we are narrowing our guidance to a range of $620 million to $635 million, reflecting the incremental headwinds from China and foreign exchange. We are encouraged that our businesses are performing as expected and we achieved our revenue targets in the first half of the year. Orders held steady, supporting a first half book-to-bill of 1.01 and higher in important market areas like CDMOs and new modalities. Our opportunity funnel continued to strengthen as we moved through the first half of the year. The funnel is up significantly versus the same period in 2023. Our healthy funnel was reflected in our orders performance for the quarter and is another lens to support to our view that the markets are more fully recovering as we move into the second half of 2024. With the positive uptick in orders and funnel strength, along with improving visibility, we expect the second half of the year revenue to be stronger versus first half. We also expect to see a return to robust revenue growth in the second half of the year, with non-COVID revenues projected to be up 11% versus same period in 2023. We expect Q4 to be an especially strong revenue quarter given the funnel and the known seasonality challenges associated with Q3. Based on these market trends and our healthy funnel, we believe we are finally seeing the turnaround in the markets, and we are excited about the momentum going into 2025, where we expect to continue to grow above market. I'll now hand the call over to Olivier to talk about our franchise performance and the commercial efforts to develop a key account program.
Olivier Loeillot: Thank you, Tony. Let me provide some quarterly highlights for each of our franchises. Starting with proteins where the known headwinds of $32 million have not changed over the last six months, we're still expecting this franchise to deliver $67 million to $72 million in revenues this year. While 2024 will be a down year for proteins, we're very optimistic about a solid rebound in 2025, based on the new protein A resin we launched with Purolite in the map space, and the impact of the Tantti technology in new modality markets. The pending acquisition of Tantti is a strategically important technology play for the company. It allows us to combine Tantti’s microporous bead technology with the affinity content from Avitide, and our pre-packed OPUS Columns. Because we've already been working with Tantti scientists for a couple of years, we expect to be able to launch our first resin under Tantti’s DuloCore brand as soon as quarter four. So, exciting time for this franchise as we built out a best-in-class affinity resin portfolio to disrupt and take share in both markets with Purolite and new modality markets with Tantti. Our filtration franchise continued to perform well, with revenues up mid-single digits in Q2, and excluding COVID, up almost 10% year-to-date. Total orders have also been robust, greater than 20% year-to-date. Strength in the business is coming from ATF Tangenx flat sheet cassettes and systems. Total ATF systems revenues were up greater than 50% in the quarter and 40% for the first half of 2024. In Q2, we saw accelerating demand for Tangenx, which was up 30% year-over-year. The flat sheet cassette uptick is another sign that destocking is behind us, as we have a broad customer base spanning CDMO and pharma. Finally, ARTeSYN systems had another strong quarter, where we continue to differentiate ourselves on systems with integration of C Tech’s flow analytics technology. Moving to chromatography, while our total chrome revenues were slightly down year-on-year, we saw sequential growth of about 10%. And the most significant piece of the franchise, our OPUS portfolio, showed positive signs of recovery, with revenues up high single digits in the quarter and mid-single digits for the first half of the year. Otherwise, we saw a significant increase in chromatography demand, up greater than 50% in the quarter, nearly 20% sequentially, and up 15% year-to-date. For OPUS, orders in the quarter and first half of the year have been robust, up greater than 20% through the first six months of 2024, driven by strength in new modalities. On top of this, our chrome systems had a strong quarter on orders as we continue to see traction for our ARTeSYN product line in the field. Our analytics business had a nice pickup in revenues versus Q1 and was up mid-single digit year-over-year. We continue to focus our efforts on new modality adoption and promoting the flow technology as part of our ARTeSYN system product offering. Finally, a big area focus for me over the last nine months was building out our key account strategy for the company. I am delighted that our key account management team now covers 20 of our top accounts. We are very happy about the impact it has already had in 2024, and believe it'll be key to our growth in 2025 and beyond. We had numerous meetings with pharma C-suite team to present on our most recent innovations and broad product portfolio. The feedback is very positive, especially on the depths and breadths of what we now bring to the table. The key for me as I move into the C role is to maintain the focus on innovation and impact of disruptive technologies in our markets and make sure that we have increased visibility at a senior level across our customer base. We expect this, in combination with our funnel of opportunities that are moving from early to late stage clinical and commercial, will be the catalyst for sustained long-term growth, consistently above the market growth rate. Now, I will turn it back to Tony to wrap up the business section.
Tony Hunt: Yes, thanks, Olivier. So, in summary, we've completed a solid first half to 2024, with revenues right in line with our expectations and orders tracking ahead of revenues by 1%. We are encouraged by the continued strength we're seeing in pharma, consumables, and new modalities, and by the positive uptick we saw in CDMOs and capital equipment in Q2. There's still a lot of work to be done, but we're excited about moving back into growth mode in the second half, with projected non-COVID growth of 11% at the midpoint of our guidance. We remain confident about 2025, as many of the one-time headwinds facing Repligen here in 2024 will be behind us. On a personal note, I would like to thank our employees, customers, and investors for giving me such support over the last 10 years. It's been a brilliant experience. When I look to the future, I'm very confident about the success of Repligen and the company is in very capable hands with Olivier at the helm. Now, I'll hand it over to Jason for the financial update.
Jason Garland: Thank you, Tony, and good morning, everyone. Today, we reported our financial results for the second quarter 2024, and have updated our financial guidance for 2024. Revenue in the second quarter was up approximately $3 million sequentially from the first quarter as we delivered revenue of $154 million. This is a reported decline of 3% year-over-year or down 5% on an organic basis. Recent acquisitions contributed 3% of our reported growth, and currency and COVID created about a 2% headwind. Excluding proteins, with a known headwind of approximately $8 million per quarter, our other franchises grew 3%. For the first half of 2024, we reported $305 million of revenue, in line with our expectations. First half revenues decreased 11% year-over-year, but were up 5% if you exclude known COVID and protein headwinds. As Olivier shared color on our franchise performance, I'll provide more detail on the performance across our global regions. In the second quarter of 2024, North America represented approximately 50% of our global business, while Europe represented 36%, and Asia Pacific and the rest of the world represented 14%. Within Asia, China was down 38% versus the second quarter of 2023, and represented 4% of our total business in the quarter. North America grew year-over-year on strength across all franchises except proteins, and Europe was down 3%, driven entirely by the decline in affinity ligands. All regions are up high single-digit to low double-digit on orders in the first half of 2024, with the exception of China. China was down more than 20% in the first half of the year and almost 30% when you compare first half of 2024 to the second half of 2023. We have seen no signs of recovery and do not expect to see a turnaround in 2024. Based on our first half performance, we now expect China to be approximately 4% of our worldwide sales versus our previous range of 5% to 6%, which essentially drives $10 million of our drop in revenue guidance. Second quarter 2024 adjusted gross profit was $76 million, a $4 million decrease in year-over-year on $5 million of lower revenue. With this, we delivered a 49.6 adjusted gross margin. This is down 60 basis points versus last year, driven by volume and incentive compensation headwind, mostly offset by year-over-year productivity. That said, it was sequentially up 100 basis points from the first quarter. First half of 2024 adjusted gross margin was 49.1%, and remains consistent with achieving our 2024 total year guidance of 49% to 50%. Continuing through the P&L, our adjusted income from operations was $16 million in the second quarter, down approximately $14 million compared to prior year. The majority of this decline was driven by $9 million of incremental incentive compensation, and the remaining from volume and inflation, partially offset by some price improvement and productivity savings. Sequentially, our adjusted operating expenses were down $1 million from the first quarter, and we were executing an estimated 7% further reduction of adjusted operating expenses in the second half versus the first half run rate. While this is a meaningful reduction, we have also increased our investments in the commercial team to add more critical key account resources. We're also seeing that the impact of some of our cost reduction initiatives will move to later in the year. Therefore, we are updating our full-year guidance to reflect an additional $3 million of adjusted operating expenses. Our second quarter 2024 adjusted operating income margin improved sequentially by approximately 200 basis points to 10%. On a year-over-year basis, adjusted operating income margins are down roughly eight percentage points, driven by the increase in incentive compensation noted earlier and lower volume, with some offset from year-over-year cost reduction initiatives. Our second quarter 2024 adjusted EBITDA margin rate was approximately 15%, which reflects the five percentage point drive from depreciation. With cost optimization and margin expansion remaining a priority, we expect to continue to execute programs and evaluate the need for future optimization and restructuring actions. That said, we incurred less than $1 million of restructuring charges in the second quarter. Adjusted net income for the quarter was $19 million, down $11 million versus last year. This was driven by the $14 million drop in adjusted operating income, offset by greater than $1 million of higher interest income, net of interest expense from improved interest rates on our cash position, and it includes approximately $1 million less adjusted tax provision. Our second quarter adjusted effective tax rate was 18.1%, which includes a discreet benefit from stock-based compensation. Given the first half run rate, we are updating our total year adjusted effective tax rate outlook, and expect it to be approximately 20%, down from the prior guidance of 21%. In addition, we believe that the continued strength of our cash balance and interest rates, will allow us to increase our adjusted other income outlook by approximately $6 million. Adjusted fully diluted earnings per share for the second quarter was $0.33, compared to $0.53 in the same period in 2023. Finally, with a strong generation of cash flow from operations in the quarter, we increased our cash position to $809 million, up $29 million from the first quarter, and up $58 million from the end of 2023. I'll now move to an update on our guidance for the full year of 2024. I'll speak to adjusted financial guidance, but please note that our GAAP and non-GAAP reconciliations for our 2024 guidance are included in the reconciliation tables in today's earnings press release. And for further clarity, our guidance is fully inclusive of the FlexBiosys and Metenova acquisitions we made in 2023, but excludes any impact from the pending acquisition of Tantti. As highlighted earlier by Tony, we have updated our total year adjusted guidance ranges that we shared in February and April. While we were maintaining guidance within our range, we now expect total revenue in 2024 to be between $620 million and $635 million. We expect year-over-year revenue growth in the second half of the year. At our guidance midpoint, we expect total revenue growth in the second half of 2024 to be 8% year-over-year and non-COVID revenue growth to be 11%. Overall, for the full year, we expect 2% to 5% of growth for our non-COVID business, with M&A contributing approximately three percentage points of that growth. We still expect to deliver adjusted gross margins in the range of 49% to 50%, essentially flat to 2023. We now expect our adjusted income from operations to be between $76 million to $81 million, or 12% to 13% adjusted operating margin rate, down $7 million and down one percentage point from our prior guidance, respectively. $4 million of the $7 million decline is coming from lower volumes associated with our revised revenue guidance, and the remaining $3 million is coming from the increase in adjusted operating expenses discussed earlier. With the first half adjusted operating margin of 9%, we expect to be able to reach the 12% to 13% through both volume leverage and from further operating expense cost reductions in the second half. Adjusted EBITDA margins are now expected to be in the range of 17% to 18% for the year, reflective of the exclusion of roughly 500 basis points of fixed depreciation costs from capacity expansions we have made. As discussed earlier, we expect our adjusted other incomes to now be approximately $24 million, and our 2024 adjusted effective tax rate is now expected to be an estimated 20%. With these improvements in adjusted other income and adjusted effective tax rate, we were able to offset the adjusted operating income reduction, and we are holding our guidance for adjusted net income at $80 million to $84 million. and our adjusted diluted earnings per share of $1.42 to $1.49. In closing, we are encouraged by the momentum we are seeing in the market coming out of the second quarter. We believe that our focus on key accounts, delivering on innovation, continuing to acquire differentiated technologies like Tantti, and executing on our revenue and profitability goals, sets us up well for a successful exit through the year and into 2025. And with that, I'll turn the call back to the operator to open the lines for questions.
Operator: [Operator Instructions]. The first question comes from Rachel Vatnsdal with J.P. Morgan. Please go ahead.
Rachel Vatnsdal: Perfect. Good morning you guys. Thanks so much for taking the questions. So, my first question is just around the order book. It's great to see some of this continued progress on the order intake, especially within the CDMO customers. You've been vocal about some of that lumpiness that you had been seeing on the CDMO side, and today you called out a book-to-bill of over 1.4, and I believe you said order growth of over 20% within CDMOs as well. So, can you unpack for us what really drove that strength in the CDMO market, and how durable do you think some of this strength is? And then within those CDMOs, are there any areas that are rebounding faster, whether that's consumables or equipment or certain modalities as well?
Tony Hunt: Yes, thanks, Rachel. Yes, look, in general, I think when we look at our book-to-bill over the last four quarters, we've been very consistent as a company. It's been around one, not a little higher than one. I think the average over the last four quarters has been 1.04. So, I think we've shown some consistent results. We talked at the end of last year about having the first quarter in 2023, where we actually saw really strong CDMO activity. That was in Q4, and that came from our top 10 CDMOs. So, really strong order quarter in Q4 of last year. We had a lighter quarter in Q1 where we had a couple of the large top 10 CDMOs were down on their ordering pattern versus what we've seen in the past. In Q2 was a little different. In Q2, for the first time we saw the tier two CDMOs come back. If you looked at the last six quarters, the tier two CDMOs have been flat, basically ordering the same amounts quarter after quarter, but not seeing any uptick. So, it was really encouraging that the growth we saw in CDMOs in Q2 did come from the tier two CDMOs. So, if you look at it, two of the last three quarters have been very encouraging for CDMOs. Q1 has been light. I think the next couple of quarters will tell us a lot. And just as an aside, the strength we saw in CDMOs coming from the smaller CDMOs, we also saw a similar pattern in the pharma biotech space. So, again, another kind of encouraging sign that the long tail of accounts that we have and everybody else has in the industry is beginning to show some light.
Rachel Vatnsdal: Great. And then just on my follow up for seasonality, you called out some seasonality in the prepared remarks for 3Q. I mean, we've heard some varying comments on seasonality across your peers that have reported so far. So, could you walk us through, what are you guys assuming in terms of sequential revenue growth into 3Q and then sequential revenue growth into 4Q as well? And then more broadly, can you just remind us, what do you consider normal seasonality throughout the year for Repligen? Thank you.
Tony Hunt: Yes, so maybe the last part of your question, seasonality for Repligen and for our industry tends to be strong Q2, strong, very strong Q4, lighter start to the year, with Q3 being the - typically being the lightest quarter. Now, that's been weird for the last few years, but if you look at it over the course of 10, 15, 20 years, I don't think there's anyone in the industry in bioprocessing that wouldn't tell you that Q3 is typically the lighter quarter. I think we're back to more of a normal year. If you look at our performance this year, first half of the year ex-COVID, ex-proteins where you know we had this protein headwind, we're up 4% on revenue. If you go into the second half of the year, we're calling second half of the year as 11% growth ex-COVID for Repligen. And even without COVID, we’re going to be up 8% at our midpoint. So, I think that's a really positive sign for us. And we do expect Q4 to be a very strong quarter. We have a strong funnel. We have a lot of orders that came in in Q2 that are going to ship out in Q4. So, we're definitely heavily weighted towards Q4 versus Q3.
Operator: The next question comes from Dan Arias of Stifel. Please go ahead.
Dan Arias: Good morning, guys. Thanks for the questions. Tony, new modality orders up 40%. That's pretty solid. Do you think that that says something about where the industry is in terms of improvement, or is there a sensitivity to individual projects or customers that kind of makes it less of a broad-based comment? And then relatedly, at this point, do you have like a cell and gene therapy growth forecast for the year?
Tony Hunt: Yes, we haven't put a cell and gene therapy forecast in place for the year. And Dan, you might remember, we turned - we've moved cell and gene therapy into a new modality. So, it's cell gene therapy, mRNA, exosomes, everything that you would put in new modalities is what we're capturing overall and when we talk about the growth. And so, when we look at last year, this year, I would say the biggest strength for us has been our top 20, 25 accounts. It really hasn't been the long tail of cell and gene therapy and new modality accounts. It's really been the top 20, 25 who have been scaling. And that's what we saw in Q1. That's what we saw in Q2. Having a book-to-bill that's slightly above 1.1 was very encouraging for this space, but the growth is coming from late stage commercial. And I'm not sure, Olivier, if you want to add anything to that.
Olivier Loeillot: Yes, no, we are obviously benefiting from those late stage and commercial drug moving forward. And I actually mentioned, our first half revenue were up more than 10%, and the orders were up more than 20%. So, we really have great traction on these modalities across the board right now, Dan.
Dan Arias: Okay, helpful. And then maybe, Jason, generally speaking, when it comes to forecasting, do you feel like predictability is getting better here? I mean, destocking has run its course, small and mid biotech are no longer in free fall. So, obviously we'll have to see how the back half shake out, but come to fall, we're all going to be trying to dial in 2025. And so, I'm just kind of curious whether you're more optimistic that as you start to talk about 2025 and the outlook there, that the error bars around that outlook for next year should be tighter, visibility can be better. And so, therefore I guess the idea would be that an initial forecast just has a better chance of being the one that you finish with.
Jason Garland: Yes. Look, I mean, as we continue to see more of the green shoots and the positive signs, that gives us just again, an overall, I’d say higher confidence in what we're seeing in the market. We've also talked about the growth in our funnel, right, and our opportunity pipeline. And then also, as we've kind of normalized back to a more traditional backlog, right, going into a quarter and going into the year. So, I think all of those elements help give us better visibility and certainly we'll have more of that as we exit 2024 and go into next year.
Operator: The next question comes from Jacob Johnson of Stephens. Please go ahead.
Jacob Johnson: Hey, thanks. Good morning. And Tony, congrats on a great run. On China, we've heard kind of muted commentary around that end market, but you guys kind of called out incremental pressures. Can you just unpack what you're seeing there? And then I'm just curious on China, given this will be 4% of your business this year, much smaller exposure than previously, does that change your strategy around that end market?
Olivier Loeillot: This is Olivier again. I’ll take this question. I think we’ve seen really further deterioration in orders that we went through Q2, and only the forecast from our team is pretty tough for the second half of this year, which is why we decided to reduce our guidance expectation by 10 million, and this is really coming from China. So, we've taken some action down there. We've even decided to right-size the team in the region, and we're now looking like we'll land probably around $25 million in 2024. So, it's a significant drop for us this year versus last year, for sure.
Jacob Johnson: Okay, got it. And then maybe just, Jason, on margins and kind of pacing in the back half of this year, you talked about I think another 7% to come out in 2H. Can you just help us on the timing of that between 3Q and 4Q as we're thinking about modeling OpEx in the back half?
Jason Garland: Yes, definitely. Look, I mean, for margins, we've been continuing to drive the optimization and cost-saving activities that we've talked about. Our RPS programs, that consolidation, being a very diligent on our spending. So, you saw some of that improvement already. In the second quarter versus the first quarter, we went up in both gross margin and then also the operating margin. Gross margin is already tracking at the total year guide and 2Q, and expect that to kind of stay there, maybe a little higher in the fourth quarter as that goes more the high end of the range that we've given, maybe slightly above. And then as we continue to take actions and see the benefits of the actions that we've taken that are already in flight at the operating expense level, then again, we kind of see that step again in third quarter. And then fourth quarter, again, when you look at the overall guide we've given from a revenue profile, that's where you'll really see a bit higher leverage than you get into the fourth quarter. So, step up in three and then a bit more in the fourth quarter, and that'll get us to around that 12% to 13% margin for the year. And again, that that's really driven by both volume improvement, as well as - and the volume leverage you get with that, as well as the operating expense reduction. So, we continue to execute.
Operator: The next question comes from Puneet Souda of Leerink Partners. Please go ahead.
Puneet Souda: Yes, hi guys. Thanks for my questions, and Olivier, congrats. Great to have you on board. And Tony, it's been truly a pleasure working with you over the years. So, my first question is on CDMOs. Tony, can you tell a little bit more about what is driving the growth behind the CDMOs? You pointed out growth in tier twos. Is it biotech funding? Is it modality specific? We continue to hear about some facilities being underutilized and rationalization going on in facilities. So, just want to understand the dynamics here, and how much of this is maybe the new modalities running through CDMOs and maybe the DMD drug picking up?
Tony Hunt: Yes, so on the CDMOs, I would say that early days, right? So, two out of the last three quarters looked good. One quarter was the, our top 10 CDMOs showing real order growth. And we're talking about orders here because revenue's been really light from the CDMO space. And then obviously in Q2, it was more the tier twos. So, we're really encouraged that the tier twos have bounced back. We think it's a combination, honestly, of destocking finally being over where a lot of the CDMOs either had inventory on hand or had a lower number of projects that were coming through. So, there's been pick up in projects. It's been a pickup in activity and we think that's encouraging. But obviously we need to see a few more quarters of that as we go through the second half of the year.
Puneet Souda: Okay, that's helpful. And then one of the questions we continue to get frequently is 2025. Could you maybe elaborate a jumping off point from the fourth quarter? And is it fair to say with the guidance now lower to flat for this year, is low teens to mid-teens the right way to think about it versus the 15% long-term, 15% to 20% long-term growth that you had outlined previously?
Tony Hunt: Yes, good question, Puneet. I'll say the following. We're going to wait until the end of the year to talk about 2025. That said, second half of 2024, we're going to be up 11% ex-COVID. So, I think that's very encouraging. We think our forecast or guidance that we’ve put in place for the year, for the second half of the year, is very achievable. We fully expect that when we get into 2025, we are going to grow above market. And so, we'll wait until we get to end of the year and we'll give a lot more commentary on 2025, but obviously very encouraged by kind of how we performed in the first half of the year. You can see where we're going in the second half of the year and next year, we're confident about being above market growth.
Operator: The next question comes from Justin Bowers, Deutsche Bank (ETR:DBKGn). Please go ahead.
Justin Bowers: Hi, good morning, everyone. So, two questions, one on the opportunity funnel and then one more strategic. But could you talk about the funnel a little bit and how that's changed throughout the year, and maybe how things paced in 2Q and early into 3Q?
Olivier Loeillot: Yes, so the funnel continues to strengthen. I mean, our 50 plus probability funnel, we have significantly year-over-year. We're really happy about that, but it's also increasing sequentially from quarter one to quarter two, but also the total funnel also keeps on increasing. So, we’re really happy about that. With some of the newcomers we had joining the team as well, we’ve got much more discipline in quantifying and accounting for those leads, which is giving us also much more visibility, let’s say, now.
Justin Bowers: Okay. And then in terms of strategy, you just made this acquisition for the resin beads, and you've had the partnership with Purolite a couple of years ago. Can you talk about how you're approaching that market and some high-level thoughts on the opportunity there and how that can contribute to growth over the next three to five years?
Tony Hunt: Yes. So, I'll start and I'll hand it over to Olivier for some additional comments. So, nothing's changed in terms of our interaction with Purolite Ecolab (NYSE:ECL) now or going forward, because the way we view it is that our partnership with Purolite is very much on the map side, and we're fully committed to that, and we've been launching products. In fact, in Q2 we launched a brand new protein A resin that is high caustic, high capacity and also protease resistant. So, it's a unique protein A ligament resin that's being launched. And we're very hopeful about how that's going to do in the marketplace. One of the things that we tried to do when we did the Avitide deal was Avitide was really going to be our way of moving in, in a deeper way into the new modality space. The challenge in the new modality space is that the majority molecules in new modalities are very large molecules. They're like viruses. They're nucleic acids or viral vectors. It requires a very unique base bead structure. So, the typical agro beads that customers use or even suppliers use, usually do not address the need for higher capacity and higher throughput that's required in this space. So, a lot of times, people look at membranes, but then membranes have pretty low capacity. So, when we started working with Tantti, we realized that the Tantti technology is the perfect combination of our Avitide content with the base bead that gives you the attributes that I just spoke about. So, early days, very helpful that this combination is really going to unlock the power of Avitide, but without Tantti, you can't get there. So, it's the two together that will be disruptive in the industry. I'm not sure, Olivier, if you want to add to that.
Olivier Loeillot: I would just add, like you said, yes, the new modalities require new purification solutions that do not exist yet, but also customization is very important because within those new modalities, every product require a kind of very different technology. And our Avitide offering is very good because within three months, we can develop a new ligand, and within six months now with Tantti, we can have a full resin operational for customers. So, we're very excited about that opportunity here.
Operator: The next question comes from Matt Larew of William Blair. Please go ahead.
Matt Larew: Hi, good morning. There was substantial capacity added throughout COVID by you and others in the industry, and I think there was a perception in the investor community that because of the right-size in the pipelines and the funding environment, perhaps there would be a change for what historically have been very positive market forces in terms of the ability to pass through inflation, working with sole sources, et cetera. So, I'm just curious now as you sort of emerge past that destocking, what your sort of initial take is on the market forces going forward. Again, whether that's on pricing, multisource versus single source, your competitive position, et cetera.
Olivier Loeillot: Hi, Matt. I think within the bio process, product portfolio, there are a lot of different situations. I mean, and what I think Repligen is very unique about is with our innovation, when you look at the different product lines we're into, we don't have that much competition because of the innovative factors we're bringing to the table here. So, capacity, having capacity available in product in fact seems to be a real good opportunity because that will enable us to support our customer growing demand in the next few years. And then obviously if you look at some specific areas, and I would probably mention the single use industry, there is technically much more capacity available today, and probably this will generate the more competitive fight between the key actors in the field. But really, innovation is our patient for Repligen and thanks to that, we are lucky, having that available capacity is going to be a greater volume for us.
Matt Larew: Okay, thanks. And then just maybe one more follow up on the CDMO side. You referenced earlier broadly sort of equipment versus consumables. Just kind of curious, as CDMO strength broaden into tier twos, what you're seeing in terms of equipment versus consumables and if that's perhaps indicative of new projects being started versus perhaps old projects being turned on. Any additional color there would be helpful.
Tony Hunt: Yes, maybe I'll start on it. I think on the CDMO front, when we look at capital equipment and we look at the orders that came in for capital equipment, because we had a lighter quarter on revenue for capital equipment in Q2, but orders were strong, but it definitely span CDMOs and span pharma. I don't think there was a particular weight towards CDMOs in the quarter versus pharma. I think it was just across the board. And I think it reflects really the competitiveness of our RS product line, which is the ARTeSYN product line. And it's something that we've been very focused on. So, I don't think there's anything to draw in terms of whether capital equipment was stronger in CDMO versus pharma. I just think we had a healthy 0uptick in orders for the RS portfolio in the quarter. Olivier, I’m not sure if you want to add to that.
Olivier Loeillot: Nope.
Operator: Our next question comes from Conor McNamara of RBC Capital Markets. Please go ahead.
Conor McNamara: Just given some of the commentary in your prepared remarks on improving funnel and orders relative to what you talked about in Q1, why did the non-China revenue guide not increase, because everything sounds like it - the funnel's definitely improving. So, how did that flow through to a guidance increase on the non-China business?
Tony Hunt: Yes, so good question, Connor. Look, when you look at our guidance, you're right, the guidance sort of 1% drop off midpoint is really coming from China. We think we put honestly the right guidance in place at the beginning of the year. Everything is holding. We believe we'll be in the range that we have outlined today. The only drop off really is coming from China. We expect by the end of the year, we're going to be in that range. We’re showing consistency from quarter to quarter, which I think is very encouraging, and we're showing, Connor, 11% growth ex-COVID in the second half of the year. I think that's really encouraging.
Conor McNamara: Great. Thanks for that, Tony. And then just can you comment at all on the intra quarter progression in activity and if you can any what progress you're seeing so far in July?
Tony Hunt: So, the intra-quarter progress, Connor, in Q2 or intra-quarter progress Q3?
Conor McNamara: Yes, Q2 and how July's stacking up so far?
Tony Hunt: Yes, so Q2 I think was - as you know, when we reported out at the end of April, we had a solid April. And then I think June was a little stronger, was stronger than May, but there was nothing - they were all pretty consistent, with June being - definitely being stronger than the first two months. And then July, I’ll just call it start, I mean, we’re still early days of the quarter and typically this is one of the later quarters just simply because of seasonality and most of Europe's on vacation for at least the month of August.
Operator: Our next question comes from Dan Leonard of UBS. Please go ahead.
Dan Leonard: Thank you very much. I have a follow up question on sales pacing in the second half of the year. Can you clarify, you expect Q3 revenue to be down sequentially and also lower than Q1 revenue? Is that correct?
Jason Garland: No, we're not saying that it's going to be lower than Q1 revenue. We're thinking it's in that range of Q1 to Q2. So, it's definitely in that 151 to 155 range. That's probably where we see it.
Dan Leonard: Got it. And then, Tony, can you clarify what is the order growth assumption in Q3, sequentially order growth assumption required to hit that fourth quarter ramp?
Tony Hunt: Yes, there's no - like, our order assumption is the second half of the year order assumption. So, the order assumption is 4% order growth, and the second half of the year to hit the midpoint of our guidance, that it's 5% revenue growth in the second half of the year to the point of our guidance.
Operator: The next question comes from Paul Knight of KeyBanc. Please go ahead.
Paul Knight: Could you talk to what portion of revenue, what percent of revenue is from, I would say new modalities, but I think the definition more would be where you really have limited competition such as OPUS, VPE, ATF, Avitide, what's your kind of percentage range on that, Olivier or Tony?
Tony Hunt: Yes, so Paul, I would say on new modalities, it's about 20% of our revenues coming from new modalities. Obviously, we've had a good first half of the year. The growth is coming from the top 20, 25 accounts. I think it's really hard to bundle all the other product lines that we have that we would say are somewhat unique to Repligen in general. If you take outside our food management space, everything else is somewhat unique and independent. So, hard to put a number on it, but I would say in the second half of the year, the 11% growth ex-COVID is probably a good proxy for how those businesses are all growing in the second half of the year.
Paul Knight: And then the last question on my side would be, under the account management structure that you've implemented, Olivier, how much of the growth we're seeing is coming from that? Or I guess a better way to think about it, as we think about 11% growth, how much of that is coming from this effectiveness of the sales change? Is it a half, a quarter? Can you talk to that? Thanks.
Olivier Loeillot: No, actually, so it's still a little bit early days as you know, as we really put in place that organization about a year ago or so. We are really off to a very great start. In fact, the performance board from the sale and holder point of view is really great, and so far we really want to see how 2024 plays out, and then we will be able to give more details probably by 2025. But yes, the traction we're getting from the key account team is absolutely excellent right now.
Operator: The next question comes from Matt Hewitt of Craig-Hallum Capital Group. Please go ahead.
Matt Hewitt: Good morning and thank you for taking the questions. Maybe first up on a high-level view, some of your peers have talked about or have noted a lag from the improving funding environment to the orders and purchases, yet you spoke to a pretty strong book-to-bill, a strong order flow. Are you maybe seeing earlier progress because of the funding, or is there a chance that you could see an acceleration even in some of the ordering patterns that you've already seen here in Q2?
Tony Hunt: Yes, I think the commentary from our peers is consistent with our thoughts and feelings as well. There definitely is a lag from improving biotech funding to orders. There's no doubt about it. So, when we look at our Q2, and rightfully you're pointing out that our book-to-bill was higher than what others have seen, I think it's more around the consistency that we've been able to put into how we perform as a company over the last four quarters. So, we've been around that 1.0, 1.04, I think is the average. As Olivia said earlier, we have a lot of unique products in our portfolio. So, I think that helps a little bit. We also probably didn't have as much of the destocking to deal with as some of the other players in the industry. So, I think that's also positive for us, but we feel like this as being the turning point in the markets and we expect as we move into this high single-digit overall growth to low double-digit ex-COVID, that that's a real positive sign as we exit 2024, moving into 2025.
Matt Hewitt: Got it. And then maybe separately, you're implementing another 7% cost reduction here in the second half. Is there any risk that the markets come back faster than you're forecasting or anticipating and you kind of get caught a little flatfooted from a headcount perspective. I think this is what the third cost optimization that you've implemented here in the past year or so, and I'm just wondering if there's any risk that if the market's come back quickly, you might not be able to adapt fast enough.
Tony Hunt: I think we feel like we’re well, I'll say, set up to execute. A lot of the cost savings that will continue to fall through in the second half, have been continuing within and flight and happen to be more on the operating expense side. Certainly, at the factory level, we have that capacity to grow here in the second half and be established to go into 2025. So, I don't really see that as a risk for us. We've been managing this very closely and have good line of sight.
Jason Garland: Hey, and Matt, I wouldn't think about it as cost reductions as most - it's more like we are now in a mode where we've put a lot more focus on productivity and insourcing because of all the deals we've done over the last nine or 10 years. That gives us opportunities to reduce internal costs. So, it's kind of a bigger picture cost reduction, but there's a lot of positive things going on internally in the company that are more productivity-related, insourcing-related, just looking at supplier management. All those things help towards an improving margin profile for the company.
Operator: Our next question comes from Matt Stanton of Jefferies. Please go ahead.
Matt Stanton: Hey, thanks. Maybe one for Tony or Olivier. I want to ask a question that was talked about a little bit earlier. You talked about your ability to drive above market growth here in the back half of the year and 2025. I guess the question is, what is market growth? How do we think about the growth algorithm for the industry going forward? Clearly, mads remain a big driver, commercial volumes, new modalities scaling up, biotech funding a little better, but China's tough. There's an ongoing debate on yield improvements, pricing. There's a lot of moving pieces, but if you had to package it up, how do we think about kind of market growth going forward? Should it be at call it pre-COVID levels, and I guess it's less about Repligen's ability to outgrow the market and really what is the market growth you're outgrowing? Thanks.
Tony Hunt: Yes, the way I look at it is you can see the progress that everybody in bioprocessing has made, especially in Q2. So, as our peers reported out over the last week to 10 days, I think there's a lot more green shoots now than there was 12 months ago. And yes, we need to - it needs to be determined a little bit what overall market growth is going to be as we go forward. We're not the market leaders, so it's kind of hard for me to tell you that the whole market growth is going to be X percent in 2025. I think what we do know is historically 8% to 12% has been a really good proxy over the course of 5, 10, 15 years to represent market and bioprocesses. So, whether the overall market growth next year is at the low end of that - medium end of that, that remains to be seen and we'll see when the bigger players report out at the end of the year or actually beginning of next year on what they see as overall market growth. But it's definitely going to be better than 2024 and I think we're trending in the right direction for everyone.
Matt Stanton: Thanks. That's helpful. And Jason, maybe one on margins, your updated guide, probably kind of mid-teens margins in the back half of the year. Any more color you can provide as we think about a jumping off point for 2025. Understand a lot will depend on where top line lands next year, but in terms of cost outside efficiency, sounds like a little bit of spending is coming back in on the commercial side. Can you maybe talk a little bit about kind of what's in your control for 2025 and what's tied to the top line? And then any finer point you could put on potential incremental margins as the top line comes back and we return to double-digit next year. I think the second half incrementals here are pretty healthy. So, any finer point you can put on as we think about incrementals for 2025? Thanks.
Jason Garland: Yes. Well, certainly we’re not ready to issue our full guide on - or a guide on 2025, but I go back to Tony's point about, we've got a bigger picture effort on how we continue to manage costs and drive efficiency each and every day. And so, that will certainly be a tailwind for us as we go into 2025. Also, certainly as you look at the profile of profitability through, as we've gone from first quarter to second quarter and as we roll in third to fourth, that gives us a good jump off point as well as we go into the 2025. And again, the framework by which we'll ultimately guide on 2025 will be continuing to drive gross margin improvement and then getting more leverage, if you will, on top line growth outpacing our OpEx, and that's where we'll really see it fall through at the operating margin level. So, I think we're positioning ourselves well and more to come as we get into the beginning of the year.
Operator: Our next question comes from Tom DeBourcy of Nephron Research. Please go ahead.
Tom DeBourcy: Hi guys, I'll keep this short because I know you're running over, but just if you could remind me on your visibility just in terms of - my recollection is that you typically have pretty strong visibility on a six-month basis in terms of more firm orders. And so, there's been some questions around I guess weakness in Q3 moving to Q4. And so, can you just comment a little bit more about that specific visibility that you have kind of through the end of this year?
Olivier Loeillot: Olivier here. Yes, I mean, typically before COVID, most of the bioprocessing company had about three to four months of backlog in hand. And then during COVID, it jumped up to about 10 months for each of the bio processors. So, it changed the picture completely. One of the reasons why all of this to bio has been like they're very much behind one now for the last two years because we went back to probably a typical three to four months backlog in our hands. So, when you think about it, when you have about three to four months of backlog, you typically enter in the quarter having about 60%, 65% of your quarter secured, meaning you need to collect about one third of your quarter in the quarter and then the rest you add in your backlog in the next quarter and then a little bit in the second quarter beyond. But yes, typically three to four months of back and 60%, 65% of the quarter because when you are entering the new quarter.
Operator: The next question comes from Subbu Nambi of Guggenheim Securities. Please go ahead.
Subbu Nambi: Yes, thank you guys for taking my question. Actually, an extension to Tom's question on visibility. Where would you say you have the best visibility for second half? Would it be (biotech)? Would it be CDMO versus pharma, or would it be customer sizes?
Tony Hunt: Can you repeat? That was hard to hear. Are you asking if the second half of the year is going to be more driven by CDMO versus pharma? It was hard to hear you.
Subbu Nambi: Exactly. So, the support gives you the confidence on the second half trends. Would you say you have a better handle on CDMOs or pharma, biotech or customer size?
Tony Hunt: Yes, I would say that pharma has been a real strength for us through the first half of the year. So, I expect that that will continue for the second half of the year. Consumables have been really strong first half of the year. Again, we expect consumables to stay strong. Same thing on new modalities. I think you're right, wildcards a little bit how much we see of the consistency from CDMOs and how much capital equipment comes back. But we would expect capital equipment to be stronger in the second half of the year given that customers tend to purchase in late Q3 going into Q4. So, I think for us the more important piece is for us to get midpoint of guidance, we need 4% order growth, 5% revenue growth. I think that's achievable.
Subbu Nambi: Got it. Super helpful. Thank you, guys.
Operator: This concludes our question-and-answer session. I would like to turn the conference back over to Mr. Tony Hunt for any closing remarks.
Tony Hunt: Great. Thanks, guys, for joining us and last time for me to say this, but we'll see you guys back in November, and obviously Olivier will be leading the conversation then. So, look forward to listening in on the progress that Repligen will be making as we go through the year.
Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.